Jpmorgan Chase & CO Xeris Biopharma Holdings, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XERS
# of Institutions
135Shares Held
56.4MCall Options Held
126KPut Options Held
45K-
Black Rock Inc. New York, NY10.3MShares$33.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.66MShares$24.7 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$16.5 Million61.49% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.83MShares$15.6 Million1.75% of portfolio
-
State Street Corp Boston, MA3.26MShares$10.5 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $438M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...